Observational studyBMC infectious diseases2026
Association between serum endothelial glycocalyx biomarkers and prognosis in paediatric sepsis.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate endothelial glycocalyx (eGCX) serum degradation products in children with sepsis and evaluate their association with clinical outcomes.
methodsThis retrospective observational study enrolled children diagnosed with sepsis and age- and sex-matched healthy controls. Sepsis severity was classified as mild or severe according to organ dysfunction and hypoperfusion. Severe cases were further grouped by shock presence, and shock cases were stratified based on 28-day survival. Clinical data were collected at admission, and blood samples were analysed for inflammatory markers (C-reactive protein, interleukin-6, procalcitonin [PCT]) and eGCX biomarkers (syndecan-1 [SDC-1], heparan sulfate [HS], hyaluronic acid [HA]).
resultsA total of 85 children with sepsis and 19 healthy controls were included. Serum SDC-1, HS and HA levels were significantly higher in patients with sepsis than in controls. Patients with severe sepsis showed elevated SDC-1, HS and HA levels compared with mild cases, and HA was further increased in those with shock. In the septic shock cohort, non-survivors had higher SDC-1, HS and HA levels than survivors. Moreover, SDC-1, HS and HA positively correlated with inflammatory markers and disease severity. Receiver operating characteristic analyses demonstrated that HA, SDC-1 and HS effectively distinguished severe from mild sepsis. Multivariate analysis identified SDC-1, HA and PCT as independent predictors of severe sepsis. In septic shock, SDC-1 ≥ 89.47 ng/mL predicted significantly lower 28-day survival (P = 0.004).
conclusionSerum eGCX levels are elevated in paediatric sepsis and correlate with inflammation and disease severity, indicating that eGCX biomarkers reflect the extent of endothelial injury and disease progression in paediatric sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.